Dr. Reddy's Laboratories Ltd Common Stock (RDY)

Total Costs & Expenses

₹78.21B

Quarterly · Period ending: · INR

RDY logo

RDY Total Costs & Expenses

Latest reported₹78.21B INR
RDY Quarterly Total Costs & Expenses · INR (₹2.48B → ₹78.21B)
High-resolution chart · PNG

RDY total costs & expenses history

Quarterly · INR. Dates are reporting period ends; fiscal years can differ from calendar years.

Dr. Reddy's Laboratories Ltd Common Stock Total Costs & Expenses — Quarterly (INR)
Period endingTotal Costs & Expenses (INR)
78,212,248,000
75,858,142,000
73,030,000,000
70,538,000,000
67,977,000,000
67,413,000,000
64,866,000,000
62,611,000,000
58,802,000,000
55,871,000,000
54,881,000,000
656,474,664
49,748,000,000
611,924,805
51,209,000,000
591,907,337
39,963,000,000
606,386,239
43,940,000,000
637,865,813
42,616,000,000
553,864,533
47,097,000,000
537,684,955
36,067,000,000
37,709,000,000
515,213,126
40,707,000,000
30,496,000,000
34,821,000,000
32,771,000,000
33,404,000,000
32,507,000,000
32,702,000,000
33,051,000,000
31,658,000,000
32,702,000,000
32,407,000,000
31,294,000,000
32,469,000,000
31,153,000,000
32,490,000,000
32,100,000,000
30,636,000,000
29,840,000,000
32,584,000,000
31,204,000,000
29,414,000,000
28,660,000,000
28,953,000,000
27,222,000,000
26,214,000,000
24,306,000,000
25,971,000,000
23,916,000,000
22,879,000,000
21,485,000,000
21,373,000,000
20,145,000,000
18,933,000,000
16,994,000,000
16,330,000,000
16,052,000,000
15,477,000,000
14,206,000,000
14,312,000,000
14,639,000,000
15,824,000,000
14,929,000,000
15,297,000,000
14,648,000,000
14,385,459,000
13,440,000,000
11,963,600,540
13,603,104,786
10,511,129,347
9,936,454,571
12,162,924,870
13,364,073,892
16,109,934,284
12,253,458,397
7,257,374,463
5,176,730,046
5,053,491,934
5,294,956,415
6,198,774,825
4,425,739,041
4,932,110,131
5,062,620,525
5,093,375,425
4,562,967,990
4,424,302,021
3,987,953,667
3,668,618,344
3,729,112,655
4,001,207,833
3,301,515,876
3,104,690,953
3,078,746,918
2,887,913,320
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.